Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
Recruiting · NCT06862700 · Observational (researchers observe without assigning treatment) · Lead sponsor: Xiaotong Hou
View the official record on ClinicalTrials.gov →Interventions studied
Vasopressor Exposure Levels
What this trial is about
The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.
- First-time ECMO initiation.
- Venoarterial ECMO (VA-ECMO) as the initial mode.
Exclusion criteria
- Age \<18 years.
- Severe pulmonary hypertension.
- Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).
- Severe missing data.
Where it is running
1 location listed.
- Beijing Anzhen Hospital - Beijing, Beijing Municipality, China